Navigation Links
Human papillomavirus lesion identified at the dentist

CHICAGO (February 18, 2009) - Human papillomavirus (HPV) is a group of viruses that includes more than 100 different strains or types and is the most common sexually transmitted virus. The American Social Health Association (ASHA) reports that 75 percent or more of sexually active Americans will contract HPV sometime in their lives. HPV is most commonly attributed to causing cervical cancer and genital warts, but did you know HPV also causes oral cancer?

According to a study in General Dentistry, the clinical, peer-reviewed journal of the Academy of General Dentistry (AGD), oral HPV can be detected using a very familiar, conventional device that patients may already experience in your mouth during routine procedures. This device is the VELscope. It's the fun wand that emits a bright, indigo blue light. If you've ever had a cavity, your dentist may have used the VELscope to set/harden the material used to fill the cavity.

John C. Comisi, DDS, FAGD, author of the study, discovered that the blue light emitted from the VELscope also detects cancerous oral tissue. The study explains that when emitting a specific wavelength of light into the mouth, oral fluorescence occurs, which in turn causes the tissue to emit its own light (this is called natural fluorescence). The VELscope produces a blue light that excites the oral tissue cells. Healthy cells will fluoresce back and appear green in color, while damaged and unhealthy cells will not fluoresce and thus appear as black or dark maroon areas against the green surrounding tissue.

"Surgery can remove cancerous lesions, but typically if they are found at a late stage, the surgery can be extensive," says Dr. Comisi. "Only early detection can help to minimize the extent of surgery needed to eradicate the disease. The earlier a lesion is detected, the higher the rate of survival," he adds.

The Oral Cancer Foundation says that more than 34,000 Americans will be diagnosed with oral or pharyngeal cancer this year. Of those 34,000 newly diagnosed individuals, only half will be alive in 5 years. It will cause over 8,000 deathskilling roughly 1 person per hour, 24 hours per day. The Oral Cancer Foundation warns that oral cancer is typically hard to diagnose because in early stages, it may not be noticed by the patient. The next time you visit your dentist, ask about oral cancer screeningmost people receive one during their regular dental checkup but do not realize it. AGD spokesperson, Eugene Antenucci, DMD, FAGD, says, "Dentists have a unique ability to diagnose disease at an early stage. All dentists are trained to do comprehensive oral screening examinationseach individual practitioner decides on how to implement their training in their practices."

Numerous studies have shown a connection to oral and overall health. That is why it is important to disclose all health related problems to a dentistincluding STDs. "Web site educational information also proves helpful in informing and educating patients regarding diseases such as HPV, its mode of transmission, means of prevention, and the need for regular examinations utilizing technologies such as VELscope for early detection," says Dr. Antenucci.


Contact: Stefanie Schroeder
Academy of General Dentistry

Related medicine news :

1. Former Health & Human Services Secretary Michael Leavitt To Address Health Plan Member Retention Summit
2. Former Health & Human Services Secretary Michael Leavitt to Address Health Plan Member Retention Summit
3. Tool Kit Helps Employers Team with Banks to Optimize Human Capital
4. International Humanization of Birth Conference
5. FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve
6. Targeting the protein AEG1 impairs human liver cancer growth in mice
7. Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers
8. Complete Genomes of All Known Human Rhinoviruses are Published
9. Rice U. conference to explore musics role in human cognition and behavior
10. Statement From Pew Health & Human Services Policy Program on the Introduction of the Delauro Food Safety Modernization Act
11. CPEhr Releases New White Paper Highlighting Value of Human Resources Outsourcing In A Recession
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. ... that the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior ... award celebrates exceptional special needs providers that excel in synthesizing the areas of ...
(Date:12/1/2015)... ... , ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based ... sale in the United States. Clarity is a Superior Dual Wavelength Platform which ... a single platform that is easy to own and operate. , For over ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - ... to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, ... Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker ... order to date. , The order will be from the China Disabled Persons’ ... Implant System is an effective solution for children and adults suffering from severe ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as having ... Unified Contact Center solutions targeted to the high-end enterprise contact center marketplace. , ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation ... company specializing in oncology, today announced that it has ... company,s pivotal global Phase 3 clinical trial of aldoxorubicin ... was originally estimated to be completed in Q1 2016. The ... conducted under a Special Protocol Assessment from the FDA ...
Breaking Medicine Technology: